Sakar Healthcare Limited Market Cap ($221.82 Million)
Market Cap & Net Worth: Sakar Healthcare Limited (SAKAR)
Sakar Healthcare Limited market cap. Sakar Healthcare Limited (NSE:SAKAR) has a market capitalization of $221.82 Million (Rs20.51 Billion) as of November 4, 2026. Listed on the NSE stock exchange, this India-based company holds position #15984 globally and #810 in its home market, demonstrating a 5.02% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Sakar Healthcare Limited's stock price Rs934.45 by its total outstanding shares 21949910 (21.95 Million). Also see cash flow conversion of Sakar Healthcare Limited for how efficiently the company converts equity into cash flow.
Sakar Healthcare Limited Market Cap History (2017–2026)
Sakar Healthcare Limited market cap history from 2017 to 2026. Data shows growth from $14.72 Million to $221.82 Million (33.67% CAGR). Check SAKAR stock price and chart for real-time trading data and today's change.
Sakar Healthcare Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Sakar Healthcare Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Sakar Healthcare Limited annual equity growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.09x
Sakar Healthcare Limited's market cap is 0.09 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.73x
Sakar Healthcare Limited's market cap is 0.73 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $14.72 Million | $441.71 Million | $33.78 Million | 0.03x | 0.44x |
| 2018 | $14.12 Million | $530.77 Million | $38.15 Million | 0.03x | 0.37x |
| 2019 | $15.90 Million | $682.49 Million | $70.11 Million | 0.02x | 0.23x |
| 2020 | $23.32 Million | $829.80 Million | $96.23 Million | 0.03x | 0.24x |
| 2021 | $38.61 Million | $947.39 Million | $106.83 Million | 0.04x | 0.36x |
| 2022 | $53.23 Million | $1.28 Billion | $152.43 Million | 0.04x | 0.35x |
| 2023 | $94.96 Million | $1.33 Billion | $127.59 Million | 0.07x | 0.74x |
| 2024 | $70.37 Million | $1.54 Billion | $116.71 Million | 0.05x | 0.60x |
| 2025 | $97.14 Million | $1.78 Billion | $175.02 Million | 0.05x | 0.55x |
| 2026 | $221.82 Million | $2.52 Billion | $304.85 Million | 0.09x | 0.73x |
Competitor Companies of SAKAR by Market Capitalization
Companies near Sakar Healthcare Limited in the global market cap rankings as of November 4, 2026. Also see how large is Sakar Healthcare Limited's balance sheet for a full breakdown of the balance sheet.
Key companies related to Sakar Healthcare Limited by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #516 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #536 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #591 globally with a market cap of $45.45 Billion USD ( CN¥310.59 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #618 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #516 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #536 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $46.55 |
| #591 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.45 Billion | CN¥48.69 |
| #618 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.50 |
Market Capitalization of Sakar Healthcare Limited (2017–2026)
Market capitalization of Sakar Healthcare Limited from 2017 to today. Between 2017 and today, Sakar Healthcare Limited's market cap moved from $14.72 Million to $ 221.82 Million, with a yearly change of 33.67%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Rs221.82 Million | +128.36% |
| 2025 | Rs97.14 Million | +38.03% |
| 2024 | Rs70.37 Million | -25.90% |
| 2023 | Rs94.96 Million | +78.39% |
| 2022 | Rs53.23 Million | +37.87% |
| 2021 | Rs38.61 Million | +65.55% |
| 2020 | Rs23.32 Million | +46.64% |
| 2019 | Rs15.90 Million | +12.61% |
| 2018 | Rs14.12 Million | -4.03% |
| 2017 | Rs14.72 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of Sakar Healthcare Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $221.82 Million USD |
| MoneyControl | $221.82 Million USD |
| MarketWatch | $221.82 Million USD |
| marketcap.company | $221.82 Million USD |
| Reuters | $221.82 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Sakar Healthcare Limited
Sakar Healthcare Limited research, develops, manufactures, and sells pharmaceutical products in India. The company provides liquid orals, cephalosporin tablets, capsules, dry powder syrups and injections, liquid injectable (SVP) in ampoules, vials and lyophilized injections, and oral solid dosages. Its product portfolio consists of formulations in therapeutic areas, such as anti-infective, analge… Read more